Results 231 to 240 of about 54,330 (287)

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.

open access: yesBlood
van Meerten T   +25 more
europepmc   +1 more source

Mantle-Cell Lymphoma

New England Journal of Medicine, 2022
James O, Armitage, Dan L, Longo
exaly   +5 more sources

Mantle cell lymphoma

Best Practice & Research Clinical Haematology, 2012
MCL is a well-characterized clinically aggressive lymphoma with a poor prognosis. Recent research findings have slightly improved the outcome of this neoplasm. The addition of rituximab to conventional chemotherapy has increased overall response rates, but it does not improve overall survival with respect to chemotherapy alone.
Cortelazzo S   +3 more
openaire   +5 more sources

Mantle cell lymphoma

Current Opinion in Hematology, 2004
Mantle cell lymphoma is the B-cell lymphoma with the worst prognosis. Until now, no standard treatment has resulted in cure. Improvements in understanding of the disease are needed to advance therapeutic efforts.Pathology and immunohistochemistry can identify the subset of patients with the worse prognosis.
Francesco, Bertoni   +2 more
openaire   +2 more sources

Mantle-cell lymphoma

The Lancet Oncology, 2001
During the past decade, mantle-cell lymphoma has been established as a new disease entity. The normal counterparts of the cells forming this malignant lymphoma are found in the mantle zone of the lymph node, a thin layer surrounding the germinal follicles.
I, Barista   +2 more
openaire   +2 more sources

Mantle Cell Lymphoma

Journal of Clinical Oncology, 2016
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical trials established the importance of high-dose therapy and autologous stem-cell rescue and high-dose cytarabine in younger patients and the benefits of ...
Chan Yoon, Cheah   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy